<DOC>
	<DOCNO>NCT00255450</DOCNO>
	<brief_summary>This crossover safety study evaluate safety single dose ferumoxytol compare placebo patient chronic kidney disease .</brief_summary>
	<brief_title>A Crossover Safety Study Ferumoxytol Versus Placebo</brief_title>
	<detailed_description>This double-blind , placebo control , crossover design study safety ferumoxytol compare placebo . Patients randomize receive either one 510 mg dose ferumoxytol equivalent volume normal saline follow test article give one week later .</detailed_description>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Male female patient &gt; 18 year . Have chronic kidney disease per K/DOQI guideline . Baseline hemoglobin &gt; 9.0 &lt; 12.5 g/dl Women pregnant lactating . Received another investigational drug device within 30 day . Recent parenteral oral iron therapy . Patients cause anemia . Major surgery within 30 day anticipate planned surgery study . Patients active infection . Recent blood transfusion . Patients know allergy iron product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>anemia</keyword>
</DOC>